Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Asset Resilience Ratio
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) has an Asset Resilience Ratio of 0.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ANGEN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's Asset Resilience Ratio has changed over time. See Anatolia Tani ve Biyoteknoloji Urunleri book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Anatolia Tani ve Biyoteknoloji Urunleri .
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0% |
| Short-term Investments | TL19.19 Million | 0.89% |
| Total Liquid Assets | TL19.19 Million | 0.89% |
Asset Resilience Insights
- Limited Liquidity: Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret maintains only 0.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret Industry Peers by Asset Resilience Ratio
Compare Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 36.63% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Shanghai Kinetic Medical Co
SHE:300326 |
Medical Devices | 28.89% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 48.75% |
|
Aroa Biosurgery Ltd
AU:ARX |
Medical Devices | 12.13% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
Annual Asset Resilience Ratio for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.91% | TL16.29 Million ≈ $364.77K |
TL1.79 Billion ≈ $40.02 Million |
-3.40pp |
| 2023-12-31 | 4.31% | TL84.27 Million ≈ $1.89 Million |
TL1.95 Billion ≈ $43.76 Million |
-7.48pp |
| 2022-12-31 | 11.80% | TL101.09 Million ≈ $2.26 Million |
TL856.92 Million ≈ $19.19 Million |
+5.76pp |
| 2021-12-31 | 6.03% | TL51.88 Million ≈ $1.16 Million |
TL859.77 Million ≈ $19.26 Million |
-- |
About Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid ext… Read more